Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$56,341 Mln
Revenue (TTM)
$14,086 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
14.5 %
P/E Ratio
13.5
P/B Ratio
1.9
Industry P/E
--
EV/EBITDA
9.3
Div. Yield
0.7 %
Debt to Equity
0.1
Book Value
$--
EPS
$39.2
Face value
--
Shares outstanding
106,148,000
CFO
$28,809.62 Mln
EBITDA
$33,451.99 Mln
Net Profit
$27,518.86 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
| -26.6 | -10.7 | -21.6 | -49.6 | -2.3 | -2.4 | 0.5 |
|
BSE Sensex*
| 4.3 | -0.9 | 10.6 | 6.0 | 16.6 | 19.4 | 11.8 |
|
S&P Midcap 400
| -2.5 | -0.6 | 3.8 | 4.9 | 9.6 | 11.2 | 7.2 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
| -18.8 | 21.9 | 14.2 | 30.7 | 28.7 | 0.5 | -0.7 |
|
S&P Midcap 400
| 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 | -12.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
|
522.7 | 56,340.8 | 14,085.7 | 4,499.3 | 31.8 | 15.3 | 13.5 | 1.9 |
| 308.8 | 40,158.2 | 2,348.1 | -269.7 | -9.0 | -365 | -- | 347.9 | |
| 41.8 | 11,341.9 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 101.6 | 18,753.9 | 381.0 | -1,013.3 | -247.2 | -347.9 | -- | 189.1 | |
| 159.3 | 27,142.0 | 15,497.0 | 1,334.0 | 14.7 | 20.6 | 21.4 | 4.6 | |
| 26.0 | 10,314.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 125.0 | 12,371.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.2 | 4.9 | |
| 20.0 | 14,689.9 | -- | -- | -- | -- | -- | 42.7 | |
| 288.6 | 12,781.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.3 | 1.9 | |
| 450.9 | 118,141.9 | 11,099.7 | -988.9 | -2.5 | -6.2 | -- | 7.1 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and... diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Read more
Co-Founder, President, CEO & Co-Chairman
Dr. Leonard S. Schleifer M.D., Ph.D.
Co-Founder, President, CEO & Co-Chairman
Dr. Leonard S. Schleifer M.D., Ph.D.
Headquarters
Tarrytown, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Regeneron Pharmaceuticals Inc (REGN) stood at $ 41,112 Mln as on 31-Mar-25
The share price of Regeneron Pharmaceuticals Inc (REGN) is $522.68 (NASDAQ) as of 16-Jun-2025 16:00 EDT. Regeneron Pharmaceuticals Inc (REGN) has given a return of -2.34% in the last 3 years.
Regeneron Pharmaceuticals Inc (REGN) has a market capitalisation of $ 56,341 Mln as on 13-Jun-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Regeneron Pharmaceuticals Inc (REGN) is 1.94 times as on 13-Jun-2025, a 27% discount to its peers’ median range of 2.65 times.
The P/E ratio of Regeneron Pharmaceuticals Inc (REGN) is 13.46 times as on 13-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Regeneron Pharmaceuticals Inc (REGN) and enter the required number of quantities and click on buy to purchase the shares of Regeneron Pharmaceuticals Inc (REGN).
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
The CEO & director of Dr. Leonard S. Schleifer M.D., Ph.D.. is Regeneron Pharmaceuticals Inc (REGN), and CFO & Sr. VP is Dr. Leonard S. Schleifer M.D., Ph.D..
There is no promoter pledging in Regeneron Pharmaceuticals Inc (REGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3,893
|
|
|
2,748
|
|
|
1,785
|
|
|
1,454
|
|
|
11,619
|
|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
| Regeneron Pharmaceuticals Inc. (REGN) | Ratios |
|---|---|
|
Return on equity(%)
|
15.33
|
|
Operating margin(%)
|
31.82
|
|
Net Margin(%)
|
31.94
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Regeneron Pharmaceuticals Inc (REGN) was $0 Mln.
$-6.56
(
